Cargando…
Indocyanine Green-Parthenolide Thermosensitive Liposome Combination Treatment for Triple-Negative Breast Cancer
BACKGROUND: Certain patients with triple-negative breast cancer cannot tolerate the serious adverse effects of cytotoxic chemotherapy agents, which significantly affect the disease prognosis. PURPOSE: Research into the combined use of photosensitizers and non-cytotoxic antineoplastic drugs for the s...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211433/ https://www.ncbi.nlm.nih.gov/pubmed/32440118 http://dx.doi.org/10.2147/IJN.S245289 |
_version_ | 1783531455286083584 |
---|---|
author | Jin, Xin Lu, Xinyue Zhang, Zhenhai Lv, Huixia |
author_facet | Jin, Xin Lu, Xinyue Zhang, Zhenhai Lv, Huixia |
author_sort | Jin, Xin |
collection | PubMed |
description | BACKGROUND: Certain patients with triple-negative breast cancer cannot tolerate the serious adverse effects of cytotoxic chemotherapy agents, which significantly affect the disease prognosis. PURPOSE: Research into the combined use of photosensitizers and non-cytotoxic antineoplastic drugs for the safe treatment of triple-negative breast cancer is vital. METHODS: In this study, the photosensitizer indocyanine green and the natural drug parthenolide were co-loaded into thermosensitive liposomes. Under a near-infrared irradiation, indocyanine green reached excitation levels, releasing heat, and the liposome underwent a phase transition, releasing the drug were researched. RESULTS: Thus, indocyanine green and parthenolide exert synergistic antineoplastic effects. In the nude mice xenograft MDA-MB-231 tumor model, the tumor inhibition rate of indocyanine green-parthenolide thermosensitive liposomes was approximately 2.08-fold than that of paclitaxel and demonstrated a good initial safety evaluation. CONCLUSION: Photosensitizers and non-cytotoxic antineoplastic agents in combination with nanoscale carriers should be further investigated for the treatment of tumors. |
format | Online Article Text |
id | pubmed-7211433 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-72114332020-05-21 Indocyanine Green-Parthenolide Thermosensitive Liposome Combination Treatment for Triple-Negative Breast Cancer Jin, Xin Lu, Xinyue Zhang, Zhenhai Lv, Huixia Int J Nanomedicine Original Research BACKGROUND: Certain patients with triple-negative breast cancer cannot tolerate the serious adverse effects of cytotoxic chemotherapy agents, which significantly affect the disease prognosis. PURPOSE: Research into the combined use of photosensitizers and non-cytotoxic antineoplastic drugs for the safe treatment of triple-negative breast cancer is vital. METHODS: In this study, the photosensitizer indocyanine green and the natural drug parthenolide were co-loaded into thermosensitive liposomes. Under a near-infrared irradiation, indocyanine green reached excitation levels, releasing heat, and the liposome underwent a phase transition, releasing the drug were researched. RESULTS: Thus, indocyanine green and parthenolide exert synergistic antineoplastic effects. In the nude mice xenograft MDA-MB-231 tumor model, the tumor inhibition rate of indocyanine green-parthenolide thermosensitive liposomes was approximately 2.08-fold than that of paclitaxel and demonstrated a good initial safety evaluation. CONCLUSION: Photosensitizers and non-cytotoxic antineoplastic agents in combination with nanoscale carriers should be further investigated for the treatment of tumors. Dove 2020-05-05 /pmc/articles/PMC7211433/ /pubmed/32440118 http://dx.doi.org/10.2147/IJN.S245289 Text en © 2020 Jin et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Jin, Xin Lu, Xinyue Zhang, Zhenhai Lv, Huixia Indocyanine Green-Parthenolide Thermosensitive Liposome Combination Treatment for Triple-Negative Breast Cancer |
title | Indocyanine Green-Parthenolide Thermosensitive Liposome Combination Treatment for Triple-Negative Breast Cancer |
title_full | Indocyanine Green-Parthenolide Thermosensitive Liposome Combination Treatment for Triple-Negative Breast Cancer |
title_fullStr | Indocyanine Green-Parthenolide Thermosensitive Liposome Combination Treatment for Triple-Negative Breast Cancer |
title_full_unstemmed | Indocyanine Green-Parthenolide Thermosensitive Liposome Combination Treatment for Triple-Negative Breast Cancer |
title_short | Indocyanine Green-Parthenolide Thermosensitive Liposome Combination Treatment for Triple-Negative Breast Cancer |
title_sort | indocyanine green-parthenolide thermosensitive liposome combination treatment for triple-negative breast cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211433/ https://www.ncbi.nlm.nih.gov/pubmed/32440118 http://dx.doi.org/10.2147/IJN.S245289 |
work_keys_str_mv | AT jinxin indocyaninegreenparthenolidethermosensitiveliposomecombinationtreatmentfortriplenegativebreastcancer AT luxinyue indocyaninegreenparthenolidethermosensitiveliposomecombinationtreatmentfortriplenegativebreastcancer AT zhangzhenhai indocyaninegreenparthenolidethermosensitiveliposomecombinationtreatmentfortriplenegativebreastcancer AT lvhuixia indocyaninegreenparthenolidethermosensitiveliposomecombinationtreatmentfortriplenegativebreastcancer |